Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 3/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20206774 | 0.92 | ADRA1A (0.38) | FABP4ADRA1AACACBALOX5APFEN1 | |
| SCHEMBL21533978 | 0.85 | FEN1 (0.37) | ACACBALOX5APFEN1 | |
| SCHEMBL20201600 | 0.83 | FABP4 (0.36) | FABP4ADRA1AACACBALOX5APFEN1 | |
| SCHEMBL21533824 | 0.80 | FABP4 (0.37) | FABP4ADRA1AALOX5APFEN1HCRTR1 | |
| SCHEMBL21324914 | 0.80 | FABP4 (0.37) | FABP4ADRA1AALOX5APFEN1HCRTR1 | |
| SCHEMBL20204868 | 0.77 | ADRA1A (0.40) | FABP4ADRA1AACACBALOX5APFEN1 | |
| SCHEMBL20207781 | 0.77 | ADRA1A (0.40) | FABP4ADRA1AACACBALOX5APFEN1 | |
| SCHEMBL20201618 | 0.76 | ALOX5AP (0.36) | ACACBALOX5APFEN1 | |
| SCHEMBL22751137 | 0.76 | FABP4 (0.39) | FABP4ADRA1AHCRTR1HCRTR2 | |
| SCHEMBL20207782 | 0.74 | APP (0.33) | FABP4ALOX5APFEN1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174271-B2 | 6-membered uracil isosteres | UNG, DUT, DPYD | FABP4 3772/4885ADRA1A 4587/4885ACACB 2117/4885 |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | UNG, DUT, DPYD | FABP4 3772/4885ADRA1A 4587/4885ACACB 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.